Latest News & Features
Americas
The US Food and Drug Administration approved Sandoz’s cancer product Zarxio on Friday—the first biosimilar to be rubber stamped in the US. 9 March 2015
Asia
As India appears to forge closer trade relations with the US, will the country introduce a data exclusivity legal provision and what impact would this have? LSIPR investigates. 5 March 2015
Americas
Law firm Fried, Frank, Harris, Shriver & Jacobson has added a life sciences specialist to its intellectual property litigation practice. 5 March 2015
Americas
The US Patent and Trademark Office’s Patent Trial and Appeal Board has handed down what are thought to be the first written decisions in inter partes review proceedings that concern the biopharmaceutical industry. 5 March 2015
Americas
The US Court of Appeals for the Federal Circuit has overturned a $100 million damages sum awarded to Medtronic Sofamor Danek in a long-fought patent case between the medical device maker and San Diego-based NuVasive. 4 March 2015
Americas
Life sciences lawyer Lana Gladstein has joined US law firm Nutter McClennen & Fish’s intellectual property practice as partner. 4 March 2015
Asia
The battle between pharmaceutical and generics companies in India is once again in the spotlight, with a decision pending on another compulsory licence. The players this time are Novartis and Cipla, with the former already having drawn first blood. LSIPR investigates. 3 March 2015
Europe
Previously for LSIPR, Jane Wainwright of Potter Clarkson investigated the emergence of self-colliding patent filings in Europe and their relevance to the life sciences. As the European Patent Office begins to review this issue at the highest level, she revisits the concept and why it is now being reconsidered. 3 March 2015
Americas
The FDA could approve the US’s first biosimilar product any day now. But is the country ready for the wave of biosimilar applications that
will surely follow, and how quickly can these cut-price drugs come to market? LSIPR reports. 3 March 2015
Americas
AstraZeneca has closed a deal that will see it acquire the rights to Actavis’s branded respiratory drugs business in the US and Canada, it was announced today. 3 March 2015